UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety

被引：4
|
作者：
Peeters, Sofia L. J. [1 ,2 ]
Deenen, Maarten J. [1 ,2 ]
Thijs, Anna M. J. [3 ]
Hulshof, Emma C. [1 ,2 ]
Mathijssen, Ron H. J. [4 ]
Gelderblom, Hans [5 ]
Guchelaar, Henk-Jan [2 ]
Swen, Jesse J. [2 ]
机构：
[1] Catharina Hosp, Dept Clin Pharm, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[2] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[3] Catharina Hosp, Dept Med Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[4] Erasmus MC, Dept Med Oncol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[5] Leiden Univ, Dept Med Oncol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
来源：
PHARMACOGENOMICS | 2023年 / 24卷 / 09期
关键词：
irinotecan; personalized medicine; PGx; pharmacogenetics; pharmacogenomics; precision dosing; pretreatment; UGT1A1; PHARMACOGENETICS; IMPLEMENTATION; NEUTROPENIA; TOXICITY; THERAPY; RISK;
D O I：
10.2217/pgs-2023-0096
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care. © 2023 Future Medicine Ltd.
引用
收藏
页码：435 / 439
页数：5
相关论文
共 50 条
  • [31] Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights
    Faisal, Muhammad Saleem
    Hussain, Imran
    Ikram, Muhammad Abdullah
    Shah, Syed Babar
    Rehman, Abdul
    Iqbal, Wajid
    JOURNAL OF CHEMOTHERAPY, 2024,
  • [32] Inducibility of UGT1A1 mRNA is dependent on UGT1A1*28 genotype.
    Cascorbi, I
    Remmler, C
    Haenisch, S
    Hecker, U
    Siegmund, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P34 - P34
  • [33] Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?
    Daniel, F.
    Belluomini, L.
    Lancia, F.
    Martella, L.
    Toma, I.
    Moretti, A.
    Banno, E.
    Carandina, I.
    Marzola, M.
    Fabbri, M.
    Frassoldati, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Re:: UGT1A1*28 genotype and irinotecan-induced neutropenia:: Dose matters
    Ichikawa, Wataru
    Araki, Kazuhiro
    Fujita, Ken-Ichi
    Yamamoto, Wataru
    Endo, Hisashi
    Nagashima, Fumio
    Tanaka, Ryuhei
    Miya, Toshimichi
    Kodama, Keiji
    Sunakawa, Yu
    Narabayashi, Masaru
    Ando, Yuichi
    Akiyama, Yuko
    Kawara, Kaori
    Sasaki, Yasutsuna
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (03)
  • [35] The Interplay Between Irinotecan and Bilirubin is not on the Metabolism by UGT1A1 but on the Excretion of Irinotecan
    Sasaki, Daisuke
    Tanaka, Saori
    Kadobayashi, Takaaki
    Kayano, Eiji
    Kato, Ryuji
    Ijiri, Yoshio
    Tanaka, Kazuhiko
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 665 - 665
  • [36] UGT1A1 genotype-based dose modification of irinotecan regimens: Impact on hematologic toxicities
    Tan, B. R.
    Zehnbauer, B.
    Picus, J.
    Fournier, C.
    James, J.
    Brower, A.
    McLeod, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Re:: UGT1A1*28 genotype and irinotecan-induced neutropenia:: Dose matters -: Reply
    Hoskins, Janelle M.
    McLeod, Howard L.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (03)
  • [38] UGT1A1 promoter genotype correlates with pharmacokinetics but not toxicity in patients receiving protracted irinotecan (IRN).
    Stewart, C. F.
    Panetta, J. C.
    O'Shaughnessy, M.
    Throm, S.
    Liu, T.
    Billups, C.
    Gajjar, A.
    Furman, W. L.
    McGregor, L. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 140S - 140S
  • [39] UGT1A1 and Irinotecan Chemotherapy in Azores Islands, Portugal
    Pacheco, Paula R.
    Esteves, Lisa
    Brilhante, Maria J.
    Pereirinha, Tania
    Cabral, Rita
    Branco, Claudia C.
    Mota-Vieira, Luisa
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 662 - 662
  • [40] UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
    Takano, Masashi
    Sugiyama, Toru
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2017, 10 : 61 - 68
12345